检索结果 - Elias Pintus

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

    Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report 由 Andrew D. Simmons, Minh Nguyen, Elias Pintus

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

    Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the ob... 由 Antoine Thiery-Vuillemin, Mads Hvid Poulsen, É. Lagneau, Guillaume Ploussard, Alison Birtle, Louis-Marie Dourthe, Dominique Beal-Ardisson, Elias Pintus, Redas Trepiakas, Laurent Antoni, Martin Lukáč, Suzy Van Sanden, Geneviève Pissart, Alison Reid

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study

    Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis fr... 由 Antoine Thiery-Vuillemin, Mads Hvid Poulsen, É. Lagneau, Guillaume Ploussard, Alison Birtle, Louis-Marie Dourthe, Dominique Beal-Ardisson, Elias Pintus, Redas Trepiakas, Florence Lefresne, Martin Lukáč, Suzy Van Sanden, Geneviève Pissart, Alison Reid

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

    Rucaparib or Physician’s Choice in Metastatic Prostate Cancer 由 Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel Roger Gingerich, Elias Pintus, Srikala S. Sridhar, Richard Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, John Staffurth, Charles H. Redfern, M.I. Sáez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence E. Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine Liston‐Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study 由 Wassim Abida, David Campbell, Akash Patnaik, Alan H. Bryce, Jeremy Shapiro, Richard Bambury, Jingsong Zhang, John M. Burke, Daniel Castellano, Albert Font, Vinod Ganju, Anne‐Claire Hardy‐Bessard, Ray McDermott, Brieuc Sautois, Dominique Spaëth, Éric Voog, Josep M. Piulats, Elias Pintus, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Andrea Loehr, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Jowell Go, Simon P. Watkins, Simon Chowdhury

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: